Masakazu Kobayashi, Ph.D. Joins GenoMed, Inc.'s Scientific Advisory Board
SARASOTA, Fla., Dec 26, 2001 (BUSINESS WIRE) -- GenoMed Inc. ("the Company" or "GenoMed") (Pink Sheets:GMED), a St. Louis, Missouri based medical genomics biotechnology company, announced today that Masakazu Kobayashi, Ph.D., has joined GenoMed's Scientific Advisory Board. Dr. Kobayashi is the Senior Vice President and Director of Research at Fujisawa Research Institute of America and has been employed with the Institute since 1970. Dr. Kobayashi is considered an expert within the fields of organic chemistry, signal transduction, and immunology.
Dr. Kobayashi received his Ph.D. from Kwansei Gakuin University and diversified his studies into Biochemistry and Immunology at the University of California - Irvine. Dr. Kobayashi served as a lecturer in the Neuroscience Department at the University of Okayama in Japan, and has served as an abstract reviewer for the International Society of Transplantation since 1996.
Dr. David Moskowitz, GenoMed's Chief Medical Officer, stated that, "It is a pleasure to welcome Dr. Kobayashi to GenoMed's Scientific Advisory Board. Dr. Kobayashi's knowledge and expertise within the research pharmaceutical industry will be a solid asset to the Company."
About GenoMed
GenoMed was founded with the sole purpose of translating knowledge of disease genes into better patient outcomes as rapidly and as safely as possible. The Company's business model specifically links improved patient outcomes to Company revenues through clinical treatment and genetic diagnoses of diseases.
For additional information please visit genomedics.com and/or contact Craig Hall at 941/366-6677 or email at chall@floridafunds.com.
CONTACT: GenoMed, Inc., Sarasota Craig Hall, 941/366-6677 chall@floridafunds.com genomedics.com
. |
